Cellular and humoral immunogenicity of hamster polyomavirus-derived virus-like particles harboring a mucin 1 cytotoxic T-cell epitope

Viral Immunology

Volumn 21, Issue 1, 2008, Pages 12-26

  Dorn, David C ^a   Lawatscheck, Robert ^a   Zvirbliene, Aurelija ^b   Aleksaite, Egle ^b   Pecher, Gabriele ^a   Sasnauskas, Kestutis ^b   Özel, Muhsin ^c   Raftery, Martin ^a   Schnörich, Günther ^a   Ulrich, Rainer G ^a   Gedvilaite, Alma ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VILNIUS UNIVERSITY   (Lithuania)

^c ROBERT KOCH INSTITUTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; MONOCLONAL ANTIBODY; MUCIN 1; PEPTIDE DERIVATIVE; SERYLTHREONYLALANYLPROLYLPROLYLVALYLHISTIDYLASPARAGINYLVALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL MATURATION; CELLULAR IMMUNITY; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HAMSTER; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; LEUKOCYTE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; POLYOMA VIRUS; TUMOR; VIRUS LIKE AGENT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; CA-15-3 ANTIGEN; CAPSID PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MICE; MICE, INBRED BALB C; POLYOMAVIRUS; SENSITIVITY AND SPECIFICITY; VIROSOMES;

HAMSTER POLYOMAVIRUS; MIRIDAE; MURINAE; MUS;

EID: 41349109392     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2007.0085     Document Type: Article

References (43)

1. Banchereau J, and Steinman RM: Dendritic cells and the control of immunity. Nature 1998;392:245-225.
2. Bohm W, Schirmbeck R, Elbe A, et al.: Exogenous hepatitis B surface antigen particles processed by dendritic cells or macrophages prime murine MHC class I-restricted cytotoxic T lymphocytes in vivo. J Immunol 1995;155:3313-3321.
3. Brinkman-Van der Linden EC, and Varki A: New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J Biol Chem 2000;275:8625-8632.
4. Brossart P, Schneider A, Dill P, et al.: The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res 2001;61:6846-6850.
5. Caruso M, Cavaldesi M, Gentile M, Sthandier O, Amati P, and Garcia MI: Role of sialic acid-containing molecules and the alpha4beta1 integrin receptor in the early steps of polyomavirus infection. J Gen Virol 2003;84:2927-2936.
6. Chackerian B, Lowy DR, and Schiller JT: Conjugation of a self-antibody to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001;108:415-423.
7. Chackerian B, Lenz P, Lowy DR, and Schiller JT: Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 2002;169:6120-6126.
8. Coley WB: Treatment of inoperable malignant tumors with toxins of erysipelas and the bacillus prodigiosus. Trans Am Surg Assn 1894;12:183-212.
9. Dean M, Fojo T, and Bates S: Tumor stem cells and drug resistance. Nat Rev Cancer 2005;5:275-284.
10. Del Val M, Schlicht HJ, Ruppert T, Reddehase MJ, and Kosinowski UH: Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 1991;66:1145-1153.
11. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander J, and Barratt-Boyes SM: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 1995;145:61-89.
12. Florian S, Sonneck K, Hauswirth AW, Krauth MT, Schernthaner GH, Sperr WR, and Valent P: Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leuk Lymphoma 2006;47:207-222.
13. Gedvilaite A, Frömmel C, Sasnauskas K, et al: Formation of immunogenic virus-like particles by inserting epitopes into surface-exposed regions of hamster polyomavirus major capsid protein. Virology 2000;273:21-35.
14. Gedvilaite A, Zvirbliene A, Staniulis J, Sasnauskas K, Krüger DH, and Ulrich R: Segments of Puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice. Viral Immunol 2004;17:51-68.
15. Gedvilaite A, Dorn DC, Sasnauskas K, et al.: Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology 2006;354:254-260.
16. Guermonprez P, Valladeau J, Zitvogel L, Thery C, and Amigorena S: Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002;20:621-667.
17. Hollingsworth MA, and Swanson BJ: Mucins in cancer: Protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
18. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, and Dick JE: Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 2006;12:1167-1174
19. Komagome R, Sawa H, and Suzuki T: Oligosaccharides as receptors for JC virus. J Virol 2002;76:12992-13000.
20. Lake RA, and Robinson BW: Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005;5:397-405.
21. Lawatscheck R, Aleksaite E, Schenk JA, et al.: Chimeric polyomavirus-derived virus-like particles: The immunogenicity of an inserted peptide applied without adjuvant to mice depends on its insertion site and its flanking linker sequence. Viral Immunol 2007;20:453-460.
22. Lenz P, Day PM, Pang YS, Frye SA, Jensen PN, Lowy DR, and Schiller JT: Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001;166:5346-5555.
23. Lev R: The mucin histochemistry of normal and neoplastic gastric mucosa. Lab Invest 1965;14:2080-2100.
24. MacPherson G, Kushnir N, and Wykes M: Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev 1999;172:325-334.
25. Moron VG, Rueda P, Sedlik C, and Leclerc C: In vivo, dendritic cells can cross-present virus-like particles using an endosome-to-cytosol pathway. J Immunol 2003;171:2242-2250.
26. Muller AJ, and Scherle PA: Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors. Nat Rev Cancer 2006;6:613-625.
27. Norkin LC, Anderson HA, Wolfrom SA, and Oppenheim A: Caveolar endocytosis of Simian virus 40 is followed by brefeldin A-sensitive transport to the endoplasmic reticulum, where the virus disassembles. J Virol 2002;76:5156-5166.
28. Oliveira-Ferreira J, Miyahira Y, Layton GT, et al.: Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: Enhanced memory response by boosting with recombinant vaccinia virus. Vaccine 2000;18:2923.
29. Pho MT, Ashok A, and Atwood WJ: JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis. J Virol 2000;74:2288-2292.
30. Pumpens P, and Grens E: Artificial genes for chimeric virus-like particles. In: Artificial DNA: Methods and Applications. (Khudyakov YE, and Fields HA, eds.). CRC Press LLC, Boca Raton, FL, 2002, pp. 249-327.
31. Renkvist N, Castelli C, Robbins PF, and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 2001;50:3-15.
32. Sasnauskas K, Buzaite O, Vogel F, et al.: Yeast cells allow high-level expression and formation of polyomavirus-like particles. Biol Chem 1999;380:381-386.
33. Sasnauskas K, Bulavaite A, Hale A, et al.: Generation of recombinant virus-like particles of human and non-human polyomaviruses in yeast Saccharomyces cerevisiae. Intervirology 2002;45:308-317.
34. Sedlik C, Saron M, Sarraseca J, Casal I, and Leclerc C: Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells. Proc Natl Acad Sci USA 1997;94:7503-7508.
35. Sieczkarski SB, and Whittaker GR: Dissecting virus entry via endocytosis. J Gen Virol 2002;83:1535-1545.
36. Spicer AP, Rowse GJ, Lidner TK, and Gendler SJ: Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995;270:30093-30101.
37. Suzuki S, Sawa H, Komagome R, et al.: Broad distribution of the JC virus receptor contrasts with a marked cellular restriction of virus replication. Virology 2001;286:100-112.
38. Tegerstedt K, Lindencrona JA, Curcio C, et al.: A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Cancer Res 2005;65:5953-5957.
39. Tegerstedt K, Franzen A, Ramqvist T, and Dalianis T: Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol Immunother DOI 10.1007/s00262-007-0281-8, 2007.
40. Tsunetsugu-Yokota Y, Morikawa Y, Isogai M, et al.: Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs. J Virol 2003;77:10250-10259.
41. Wierecky J, Muller MR, Wirths S, et al.: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 2006;66:5910-5918.
42. Yamamoto M, Bharti A, Li Y, and Kufe D: Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997;272:12492-12494.
43. Zvirbliene A, Samonskyte L, Gedvilaite A, Voronkova T, Ulrich R, and Sasnauskas K: Generation of monoclonal antibodies of desired specificity using chimeric polyomavirus-derived irus-like particles. J Immunol Methods 2006;311:57-70.